[AIDS 2026] IAS: Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026

Back to the "HIV and Co-Infections News" list

International AIDS Society (IAS) news release

21 July 2026 (Rio de Janeiro, Brazil) – Studies revealing the real-world impact of disruptions to the US President’s Emergency Plan for AIDS Relief (PEPFAR) and important advances in long-acting HIV prevention and treatment were announced ahead of AIDS 2026, the 26th International AIDS Conference, which will take place in Rio de Janeiro, Brazil, and virtually from 26 to 31 July.

Today’s scientific highlights press conference previewed studies selected from thousands of abstracts that will be presented next week, including:

  • A pair of studies that shed light on the real-world consequences of PEPFAR disruptions
  • Findings from the open-label extension phase of the PURPOSE 1 and 2 studies of twice-yearly injectable lenacapavir for HIV prevention
  • The first detailed results from the Phase 3 ISLEND-1 and ISLEND-2 trials of oral islatravir/lenacapavir, which has the potential to be the first complete once-weekly oral treatment for HIV
  • A study showing that HIV-specific immune activity may persist in the spinal fluid of adolescents with perinatally acquired HIV, even when the virus is suppressed in the blood

Read the full news release here.

 

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.